Shaomeng Wang, PhD
Warner-Lambert/Parke-Davis Professor of Medicine
Medical Director
Internal Medicine
Professor of Internal Medicine
Professor of Pharmacology
Medical School
Professor of Medicinal Chemistry
College of Pharmacy
Email:
[email protected]
Available to mentor
Shaomeng Wang, PhD
Professor
Manage Your Profile
Center Memberships
-
Center MemberCenter for Computational Medicine and Bioinformatics
-
Center MemberRogel Cancer Center
Recent Publications
-
Kao Y-T, Abdelalim M, Mauro C, Douthwaite JL, McGrath A, Meyer SR, Singha S, Flores Diaz D, Wang M, Wang S, Sexton JZ, Cernak T. Journal of the American Chemical Society, 2026 Aug 18;Journal ArticleA Direct-to-Biology Amine–Acid Amination for Rapid Phenotypic Profiling of Lysosomotropic Natural Products
DOI:10.1021/jacs.6c06623 -
Leng L, Huang L, Tu W, Jiang W, Rej RK, Allu SR, Wang Y, Wang M, Tošović J, Wang M, Wen B, Sun D, Wang S. Journal of Medicinal Chemistry, 2026 Jul 9; 69 (13): 15928 - 15944.Journal ArticleDiscovery of SMD-6346: A Potent, Selective, and Orally Active SMARCA2 Degrader for Targeting SMARCA4-Deficient Human Cancers
DOI:10.1021/acs.jmedchem.6c01093 PMID: 42334193 -
Ng HL, Glaser TL, Zhu J, Robinson ME, Cosgun KN, Malysheva V, Deniz O, Crump NT, Helian K, Innes AJ, Burt R, Sun L, John G, Zhou H, Kaneshige A, Bai L, Wang S, Spivakov M, Müschen M, Feldhahn N. Advanced Science, 2026 May 4; 13 (25):Journal ArticleBCR::ABL1-Induced Enhancer Reprogramming Uncovers Hypersensitivity of Ph+B-ALL Cells to Enhancer-Targeting Drugs
DOI:10.1002/advs.202517231 PMID: 41764406 -
Kandarpa M, Peterson LF, Potu H, Ramappan M, Liu Y, Polk A, Wang S, Talpaz M. Leukemia, 2026 May 1; 40 (5): 918 - 924.Journal ArticleActivity of PROTAC MDM2 degrader in primary leukemia cells and PDX models
DOI:10.1038/s41375-026-02957-8 PMID: 41986621 -
Wu D, Zhou H, Bai L, Acharyya RK, Metwally H, McEachern D, Wang M, Tošović J, Rej RK, Wang M, Wen B, Sun D, Wang S. Journal of Medicinal Chemistry, 2026 Apr 9; 69 (7): 8364 - 8387.Journal ArticleDiscovery of SD-965 as a Potent, Selective, and Efficacious STAT3 PROTAC Degrader
DOI:10.1021/acs.jmedchem.5c03767 PMID: 41871272 -
Baars B, Orive-Ramos A, Emmett MJ, Gaire B, Desaunay M, Kou Z, Li G, Adamopoulos C, Aaronson SA, Wang S, Sellers WR, Martin T, Gavathiotis E, Poulikakos PI. Molecular Cancer Research, 2026 Jan 1; 24 (1): 60 - 71.Journal ArticleRAS Mutation–Specific Responses to Paralog-and State-Selective RAS Inhibitors
DOI:10.1158/1541-7786.MCR-25-0319 PMID: 41091575 -
Corradini S, Maksimos M, Azab F, Arsalani S, Nwarunma E, Watt G, Soutar R, Powell M, Henderson R, Travers J, Chen Z, Wang S, Azab AK, Williams MTS. Leukemia, 2026 Jan 1;Journal ArticleTargeted degradation of CBP/p300 by CBPD-409 exhibits robust anti-myeloma activity
DOI:10.1038/s41375-026-03004-2 -
Chen Z, Dhruv H, Zhang X, Rej RK, Bai L, McEachern D, Kirchhoff P, Nagilla R, Jolivette LJ, Rice CT, Orth P, Strickland CO, Priestley ES, Mohammad HP, Wang M, Wen B, Sun D, Sui Z, Wang S. Nature Communications, 2026 Mar 25; 16 (1):Journal ArticleDevelopment of PVTX-405 as a potent and highly selective molecular glue degrader of IKZF2 for cancer immunotherapy
DOI:10.1038/s41467-025-58431-z
Featured News & Stories
Health Lab
Researchers find a targeted approach to shut down prostate cancer growth
Study shows a novel compound that degrades key proteins found in prostate cancer cells blocks oncogenic androgen receptor signaling.
Health Lab
Interplay between key proteins could serve as a target for cancer treatment
University of Michigan researchers have identified that the balance between two proteins—STAT3 and STAT5—is important for making tumors vulnerable to immune checkpoint therapy, and targeting STAT3 degradation is a potential novel cancer immunotherapy strategy.
